Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 9/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 9/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3003741 | 0.92 | CSNK2A2 (0.47) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL3002388 | 0.89 | CSNK2A2 (0.49) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL12543138 | 0.86 | CSNK2A2 (0.51) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL3008056 | 0.83 | CSNK2A2 (0.46) | CSNK2A2CSNK2BCSNK2A1ESR2ALOX5 | |
| SCHEMBL3012290 | 0.80 | CSNK2A2 (0.54) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL3003597 | 0.80 | PTGES (0.46) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL4000431 | 0.80 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL3010525 | 0.79 | PTGES (0.45) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL3007525 | 0.79 | CSNK2A2 (0.40) | CSNK2A2CSNK2BCSNK2A1MEN1POLB | |
| SCHEMBL3016987 | 0.79 | TRPV1 (0.45) | CSNK2A2CSNK2BCSNK2A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069321-B1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | MEDIFRON DBT CO LTD (KR) | 2016-04-13 | — | — | EP | claimed |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2010-08-05 | — | — | US | claimed |
| EP-2069321-B1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | MEDIFRON DBT CO LTD (KR) | 2016-04-13 | — | — | EP | disclosed |
| US-8580848-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-11-12 | — | — | US | disclosed |
| US-8507553-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-13 | — | — | US | disclosed |
| US-8455542-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-06-04 | — | — | US | disclosed |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-10-11 | — | — | US | disclosed |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DAEWOONG PHARMACEUTICAL CO., LTD (KR) | 2012-09-27 | — | — | US | disclosed |
| US-8263649-B2 | Benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof | MEDIFRON DBT CO., LTD. (KR) | 2012-09-11 | — | — | US | disclosed |
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2010-08-05 | — | — | US | disclosed |
| EP-2069321-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | Digital Biotech Co., Ltd. (KR) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008041826-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | DIGITAL BIOTECH CO., LTD (KR) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197685-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885 |
| US-20120259006-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885 |
| US-20120245165-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885 |
| US-20120245225-A1 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF | APP, BACE1, PSEN1 | CSNK2A2 2506/4885CSNK2B 2826/4885CSNK2A1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.